159 related articles for article (PubMed ID: 10449288)
1. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy.
Shevitz AH; Knox TA; Spiegelman D; Roubenoff R; Gorbach SL; Skolnik PR
AIDS; 1999 Jul; 13(11):1351-7. PubMed ID: 10449288
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients.
Pernerstorfer-Schoen H; Schindler K; Parschalk B; Schindl A; Thoeny-Lampert S; Wunderer K; Elmadfa I; Tschachler E; Jilma B
AIDS; 1999 Dec; 13(17):2389-96. PubMed ID: 10597780
[TBL] [Abstract][Full Text] [Related]
3. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
4. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.
Cu-Uvin S; Caliendo AM; Reinert S; Chang A; Juliano-Remollino C; Flanigan TP; Mayer KH; Carpenter CC
AIDS; 2000 Mar; 14(4):415-21. PubMed ID: 10770544
[TBL] [Abstract][Full Text] [Related]
5. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy.
Mwamburi DM; Wilson IB; Jacobson DL; Spiegelman D; Gorbach SL; Knox TA; Wanke CA
Clin Infect Dis; 2005 Jan; 40(1):167-73. PubMed ID: 15614708
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
[TBL] [Abstract][Full Text] [Related]
8. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.
Staszewski S; Miller V; Sabin C; Schlecht C; Gute P; Stamm S; Leder T; Berger A; Weidemann E; Hill A; Phillips A
AIDS; 1999 May; 13(8):951-6. PubMed ID: 10371176
[TBL] [Abstract][Full Text] [Related]
9. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips AN; Johnson MA
AIDS; 2000 Jul; 14(11):1545-52. PubMed ID: 10983641
[TBL] [Abstract][Full Text] [Related]
10. Growth velocity, fat-free mass and energy intake are inversely related to viral load in HIV-infected children.
Arpadi SM; Cuff PA; Kotler DP; Wang J; Bamji M; Lange M; Pierson RN; Matthews DE
J Nutr; 2000 Oct; 130(10):2498-502. PubMed ID: 11015480
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
[TBL] [Abstract][Full Text] [Related]
12. Viral load trend in HIV-1 seropositive patients with different CD4 cell counts before starting HAART.
Re MC; Ramazzotti E; Manfredi R; Furlini G; Vignoli M; Maldini C; Borderi M; La Placa M
J Clin Virol; 2000 Jun; 17(1):5-11. PubMed ID: 10814933
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
Bellman PC
AIDS; 1998 Jul; 12(11):1333-40. PubMed ID: 9708413
[TBL] [Abstract][Full Text] [Related]
14. Effects of HIV and antiretroviral therapy on resting energy expenditure in adult HIV-infected women-a matched, prospective, cross-sectional study.
Mittelsteadt AL; Hileman CO; Harris SR; Payne KM; Gripshover BM; McComsey GA
J Acad Nutr Diet; 2013 Aug; 113(8):1037-43. PubMed ID: 23601434
[TBL] [Abstract][Full Text] [Related]
15. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients.
Ibáñez A; Puig T; Elias J; Clotet B; Ruiz L; Martínez MA
AIDS; 1999 Jun; 13(9):1045-9. PubMed ID: 10397534
[TBL] [Abstract][Full Text] [Related]
16. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
17. Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy.
Andreoni M; Parisi SG; Sarmati L; Nicastri E; Ercoli L; Mancino G; Sotgiu G; Mannazzu M; Trevenzoli M; Tridente G; Concia E; Aceti A
AIDS; 2000 Jan; 14(1):23-9. PubMed ID: 10714564
[TBL] [Abstract][Full Text] [Related]
18. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
19. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
MacArthur RD; Perez G; Walmsley S; Baxter JD; Mullin CM; Neaton JD; ;
HIV Clin Trials; 2005; 6(3):127-35. PubMed ID: 16192247
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS
AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
